Immuneering Corp. (IMRX)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Immuneering Corp. (IMRX)
Go deeper and ask any question about IMRX
Company Performance
Current Price
as of Sep 13, 2024$2.02
P/E Ratio
N/A
Market Cap
$59.9M
Description
Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.
Metrics
Overview
- HQCambridge, MA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerIMRX
- Price$2.02+41.26%
Trading Information
- Market Cap$59.90M
- Float70.84%
- Average Daily Volume (1m)8,308,301
- Average Daily Volume (3m)4,037,625
- EPS-$1.91
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$14.08M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$14.74M
- EV-$17.46M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Factset Street Account